Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP. 

Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.